Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Assets (2016 - 2025)

Haemonetics has reported Assets over the past 16 years, most recently at $2.5 billion for Q4 2025.

  • Quarterly results put Assets at $2.5 billion for Q4 2025, down 1.6% from a year ago — trailing twelve months through Dec 2025 was $2.5 billion (down 1.6% YoY), and the annual figure for FY2025 was $2.5 billion, up 11.63%.
  • Assets for Q4 2025 was $2.5 billion at Haemonetics, up from $2.4 billion in the prior quarter.
  • Over the last five years, Assets for HAE hit a ceiling of $2.5 billion in Q2 2024 and a floor of $1.8 billion in Q3 2021.
  • Median Assets over the past 5 years was $2.0 billion (2023), compared with a mean of $2.1 billion.
  • Biggest five-year swings in Assets: soared 43.63% in 2021 and later fell 3.29% in 2025.
  • Haemonetics' Assets stood at $1.8 billion in 2021, then grew by 4.25% to $1.9 billion in 2022, then rose by 17.16% to $2.2 billion in 2023, then grew by 15.04% to $2.5 billion in 2024, then fell by 1.6% to $2.5 billion in 2025.
  • The last three reported values for Assets were $2.5 billion (Q4 2025), $2.4 billion (Q3 2025), and $2.5 billion (Q2 2025) per Business Quant data.